XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2025
Summary of Significant Accounting Policies [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets

As of June 30, 2025 and December 31, 2024, prepaid expenses and other current assets consisted of the following:

 

   As of
June 30,
2025		   As of
December 31,
2024		 
Prepaid clinical trial expenses  $402,747   $476,235 
Prepaid insurance   123,094    28,479 
Prepaid stock-based professional fees   277,625    
-
 
R&D credit receivable   46,769    46,769 
Other prepaid expenses   188,559    54,465 
   $1,038,794   $605,948 
Schedule of Anti-Dilutive Impact on the Company’s Net Loss The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss:
   As of June 30, 
Potentially dilutive securities  2025   2024 
Warrants   1,740,752    5,211,848 
Options   1,260,362    617,362 
Non-vested restricted stock awards   
-
    1,693 
Total   3,001,114    5,830,903